BioCryst prices stock offering at $9.75 per share Nov 21, 2009
Flu drug developer BioCryst Pharmaceuticals Inc. priced its 5 million common stock share offering at $9. 75 per share. (Yahoo News -- Pharmaceutical Industry News)
BioCryst Pharma to sell up to 5.75M new shares Nov 18, 2009
Flu drug developer BioCryst Pharmaceuticals Inc. said Tuesday it plans to sell as many as 5. 75 million new shares of stock. (Yahoo News -- Pharmaceutical Industry News)
BioCryst receives $22.5 million peramivir order Nov 6, 2009
BioCryst Pharmaceuticals Inc. said Thursday it will receive $22. 5 million as part of a new contract with the Department of Health and Human Services over the intravenous flu treatment peramivir. (Yahoo News -- Pharmaceutical Industry News)
BioCryst partner seeks peramivir approval in Japan Nov 5, 2009
BioCryst Pharmaceuticals Inc. said Wednesday its partner Shionogi & Co. filed for approval to market BioCryst's IV flu drug peramivir in Japan. Shionogi's filing triggers a $7 million milestone payment to BioCryst. (Yahoo News -- Pharmaceutical Industry News)
BioCryst 3Q loss grows as peramivir tests continue Nov 1, 2009
BioCryst Pharmaceuticals Inc. on Thursday reported a larger third-quarter loss as it stepped up testing of its experimental IV flu treatment peramivir. In the third quarter, BioCryst said it took a loss of $10. (Yahoo News -- Pharmaceutical Industry News)
Statin Drugs May Improve Swine Flu Survival Oct 31, 2009
BioCryst Pharmaceuticals Inc. of Birmingham, Ala. is developing peramivir with Japan-based Shionogi. (Newsmax)
BioCryst 3Q loss grows as peramivir tests continue Oct 30, 2009
BioCryst Pharmaceuticals Inc. on Thursday reported a larger third-quarter loss as it stepped up testing of its experimental IV flu treatment peramivir. In the third quarter, BioCryst said it took a loss of $10. (Yahoo News -- Pharmaceutical Industry News)
Cholesterol pills may boost flu survival Oct 30, 2009
BioCryst Pharmaceuticals Inc. of Birmingham, Ala. is developing peramivir with Japan-based Shionogi & Co.. (MSNBC -- Health)
Stock Picks: Netflix, Verizon, Shaw Group, KBR Oct 27, 2009
Plus Wall Street analyst opinions on Marvell Technology and Biocryst Pharmaceuticals. Story Tools. (BusinessWeek)
Experimental Drug OK'd Oct 27, 2009
The drug, Peramivir, is currently being developed by BioCryst Pharmaceuticals Inc. and is undergoing testing required for regular FDA approval. The FDA issued a so-called emergency use authorization late Friday that allows doctors to use Peramivir, which is delivered intravenously, in certain hospitalized adult and pediatric patients with confirmed or suspected H1N1 influenza. (Fox News)
Obama declares swine flu a national emergency Oct 25, 2009
On Friday the U.S. Food and Drug Administration issued an emergency use authorization for an experimental new drug called peramivir, made by Biocryst Pharmaceuticals Inc and licensed to Shionogi d. The authorization allows the intravenous drug to be used in hospitalized patients who cannot take pills or inhale Relenza or when Tamiflu or Relenza do not seem to be helping. (The Star Online, Malaysia)
Click to read:Families Line up for Shots as H1N1 Spreads Oct 25, 2009
And health officials have now given doctors easier access to a new weapon against H1N1, an experimental drug called Peramivir, made by Biocryst Pharmaceuticals. "It's highly potent on the H1N1 virus," said Jon Stonehouse, the President and CEO of Biocryst. (CBS News)
New IV Drug Fights Flu as Well as Tamiflu Sep 17, 2009
It has been designated for "fast track" approval by the FDA, according to its developer, BioCryst Pharmaceuticals of Birmingham, Ala. Fred Hayden, MD, of the University of Virginia in Charlottesville, says he is "very enthusiastic" about the development of an IV treatment for hospitalized patients as it makes rapid administration possible. (CBS News)
Study: New drug fights flu as well as Tamiflu does Sep 15, 2009
BioCryst Pharmaceuticals Inc., of Birmingham, Ala. is developing peramivir with Japan-based Shionogi & Co. The U.S. government gave a major grant for its development, and officials have been discussing stockpiling the drug as part of flu pandemic preparedness plans. (Orangeburg Times and Democrat, SC)
Speed up drugs; Needed in weeks... Aug 25, 2009
Reuters AlertNet - Speed up US flu drugs, vaccines-White House panel. Tue, 07:55 25 Aug 2009 GMT. (The Drudge Report)
Techne announces board changes May 20, 2009
He previously served as chief financial officer of Connectics Corp. and was a member of the executive management team at BioCryst Pharmaceuticals Inc.. His term on the Techne board begins immediately and runs through Oct. 29. (Twin Cities Business Journal, MN)
YRC Worldwide, AIG, Blockbuster Are Big Movers May 16, 2009
BioCryst Pharmaceuticals Inc., up 77 cents at $3. 19. (ABC News -- Wire)
BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology May 15, 2009
May 14 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: ) today announced long-term data from a Phase 2 study of forodesine, the Company's lead oncology compound, in patients with cutaneous T-cell lymphoma (CTCL) ... SOURCE BioCryst Pharmaceuticals. (PR Newswire)
1-Star Stocks Poised to Plunge: BioCryst? May 5, 2009
Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, flu treatment maker BioCryst Pharmaceuticals (Nasdaq: BCRX) has received the dreaded one-star ranking. With that in mind, let's take a closer look at BioCryst's business, and see what CAPS investors are saying about the stock right now. (MSNBC -- Business)
Correction: Flu treatment makers story Apr 30, 2009
NEW YORK In a April 27 story about flu treatment makers, The Associated Press erroneously described BioCryst Pharmaceuticals Inc.'s experimental drug peramivir ... BioCryst Pharmaceuticals Inc. (Yahoo News -- Pharmaceutical Industry News)
» Swine flu fears a boon? Apr 29, 2009
-based BioCryst Pharmaceuticals Inc., which is developing the flu vaccine peramivir, rose $1. 56, or 70. (Northwest Indiana Times)
Flu's bad news but shot in the arm for biotech Apr 28, 2009
-based BioCryst Pharmaceuticals, another biotech company working on a flu antiviral, rose 75 percent. The Bay Area connection: As part of its Pandemic and Bio Defense Fund, Menlo Park's Kleiner Perkins Caufield invested $20 million in Novavax and $30 million in BioCryst. (San Francisco Chronicle -- Business)
